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Step Forward in the
valuation of Transcatheter
ortic Valve Implantation*
ernard Iung, MD, Dominique Himbert, MD,
lec Vahanian, MD
aris, France
he paper by Rodés-Cabau et al. (1) in this issue of the Journal
s an important contribution in the evaluation of transcatheter
ortic valve implantation (TAVI). It is the largest published
eries reporting in-hospital and midterm results of TAVI with
he Edwards Sapien (Edwards Lifesciences, Inc., Irvine, Cal-
fornia) prosthesis. Another strength of this report is to expand
he feasibility and safety of TAVI outside a single expert center.
AVI was performed in 6 centers, thereby enabling a sufficient
umber of patients to be treated in each of them. The use of a
tandardized evaluation protocol was another important fea-
ure to ensure a homogenous use of TAVI targeting high-risk
atients. In addition, the number of patients enables results to
e assessed more accurately, predictive factors to be identified
ith an adequate statistical power, and subgroups of interest—
uch as patients with porcelain aorta or frailty—to be analyzed.
See page 1080
The high rate of procedural success (93.3%) and the low
rocedural mortality (1.7%) have improved since the first pilot
eries (2) and are consistent with recent single-center series
3,4). The 30-day mortality was 10.4% and was mainly related
o the evolutive stage of heart disease, as attested by the
redictive value of pulmonary hypertension, severe mitral
egurgitation, and the need for hemodynamic support. Severe
emodynamic impairment is also a risk factor for surgical aortic
alve replacement, and this is an incentive to avoid the
ostponement of any intervention until severe hemodynamic
mpairment, which further increases the risk of all procedures
5). The predictive value of severe mitral regurgitation deserves
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiology Department, Bichat Hospital, AP-HP, Paris, France. Dr.
ung has received speaker fees from Edwards Lifesciences, Inc. and Sanofi-Aventis.a
r. Himbert is a proctor physician for Edwards Lifesciences, Inc. Dr. Vahanian has
eceived speaker fees from Edwards Lifesciences, Inc.dditional studies, taking into account in particular the mech-
nism of regurgitation. Functional mitral regurgitation might
e expected to improve after TAVI, because of the decrease in
eft ventricular systolic pressure and delayed reverse left ven-
ricular remodeling. Conversely, there is a lower likelihood of
bserving an improvement in organic mitral regurgitation. The
mpact of mitral regurgitation on the choice between TAVI
nd surgery is an important issue, because adding a mitral
rocedure to surgical aortic valve replacement increases the
perative risk, particularly in old patients who frequently have
evere mitral annular calcification.
The 2-year survival rate of 64% is also consistent with
revious single-center reports. Besides the weight of 30-day
ortality, midterm mortality is strongly determined by non-
ardiac deaths, because 33% of late deaths were of respiratory
rigin. The small number of cardiac-related deaths can be
nterpreted as proof of sustained hemodynamic efficacy of
AVI, and this is obviously a major difference with balloon
ortic valvuloplasty. However, the weight of late deaths of
oncardiac origin also points out the need to improve the
dentification of patients whose life expectancy is more com-
romised by comorbidities than by heart disease itself. The
eight of comorbidities in midterm mortality has also been
emonstrated in surgical series, and therefore it is not surpris-
ng to observe their particular impact in a population charac-
erized by a high frequency of comorbidities. In this study
omprising approximately the same number of transfemoral
nd transapical procedures, the TAVI approach did not influ-
nce outcome. This issue is still debated and might be
nfluenced by differences in the criteria for the choice of
rocedure and the multiplicity of confounding factors. Thus,
he optimal TAVI approach remains an open question and is
lso likely to evolve with technical improvements increasing the
umber of candidates to the transfemoral route.
Another original aspect of the report by Rodés-Cabau et al.
1) is the specific study of patients with porcelain aorta or
railty. Porcelain aorta is a single condition that increases the
isk of surgery due to technical impossibility and/or hazards
elated to clamping of ascending aorta. In this context, patient
utcome is expected to be good, provided intervention on the
ortic valve can be carried out without aortic clamping, as is the
ase with TAVI. The first confirmation of good midterm
esults after TAVI in patients with porcelain aorta is a relevant
ontribution of the present study. It seems also that patients
ith porcelain aorta can be treated with the transfemoral
pproach, although the transapical route was initially favored in
his particular indication (6).
Frailty is a less well-defined but important condition to take
nto account when dealing with aortic stenosis in elderly
atients. Frailty was frequent, accounting for as many as 25%
f patients in this series. Besides comorbidities and frequently
n combination with them, it is likely to play a role in denying
ny intervention in nearly one-half of high-risk patients with
ortic stenosis (4). One of the important challenges concerning
f
l
l
s
s
t
l
f
t
a
g
a
a
l
t
l
s
s
l
i
s
I
b
b
T
R
o
c
R
1
2
3
4
5
6
1092 Iung et al. JACC Vol. 55, No. 11, 2010
Transcatheter Aortic Valve Implantation March 16, 2010:1091–2railty is to assess its impact on life expectancy and quality of
ife, regardless of heart disease and comorbidities. Despite a
ower Society of Thoracic Surgery score, frail patients had the
ame late survival after TAVI as other patients, thereby
uggesting a negative prognostic impact of frailty. However,
he current impact of frailty is difficult to assess, because of the
ack of a clear and reproducible definition. The definition of
railty used in this article is subjective and cannot be reliably
ranslated in other study populations. Future studies should
im at developing reliable indexes of frailty, and the expertise of
eriatricians is likely to be helpful in this setting.
Growing evidence now confirms that TAVI is an effective
nd useful treatment for high-risk patients with aortic stenosis
nd that it can be implemented on a nationwide basis in a
imited number of centers applying a careful screening and
raining process. Besides ongoing randomized trials, further
arge observational series of TAVI are needed to better assess the
afety of the procedure and the durability of implanted valvular
ubstitutes and to refine the identification of predictive factors of
ate results to improve patient selection. This is of particular
mportance, given the present and expected burden of aortic
tenosis in elderly patients presenting with a high-risk profile.
n this particularly heterogeneous population, much remains to
e done to better identify the patients who will derive a real
enefit from the procedure (i.e., those in whom the efficacy of
AVI will not be offset by the impact of comorbidities).
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